News

Dr Lal PathLabs Q4 Results: Profit slips 15% despite strong revenue growth; ₹4 dividend announcedDr Lal PathLabs Q4: net profit down 15.2 percent to 131.3 crore, revenue up 16.6 percent to 702.7 crore, margins narrow, board proposes 4 rupee final dividend per shareBy Megha Rani  April 30, 2026, 4:06:19 PM IST (Updated)1 Min ReadDr Lal PathLabs reported a mixed set of Q4 results on Thursday, April 30, with strong revenue growth offset by pressure on profitability margins.

The diagnostic chain’s net profit declined 15.2% year-on-year to ₹131.3 crore versus ₹154.8 crore in the same period last year.

However, revenue rose 16.6% to ₹702.7 crore from ₹602.6 crore, indicating healthy volume growth and steady demand across its test portfolio.

EBITDA increased 11% year-on-year to ₹186.8 crore compared to ₹169 crore earlier, though margins slipped to 26.6% from 28% in the year-ago period, reflecting cost pressures despite topline expansion.

The board has recommended a final dividend of ₹4 per equity share (40% on a face value of ₹10) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming AGM.

The record date for dividend eligibility has been fixed as June 26, 2026.

Shares of Dr Lal PathLabs ended lower on Thursday, April 30, by 1.7% at ₹1,374.00 on the NSE.Continue ReadingFirst Published: Apr 30, 2026 4:00 PM ISTTagsdividendDr Lal PathlabsQ4 results